Time New York: Fri 19 Apr 18:15 pm  |  Save 15% on H&R Block Online


Is Illumina (ILMN) Stock Outpacing Its Medical Peers This Year?


For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Illumina (ILMN) been one of those stocks this year? Let’s take a closer look at the stock’s year-to-date performance to find out.

Illumina is one of 756 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ILMN is currently sporting a Zacks Rank of #1 (Strong Buy).

Within the past quarter, the Zacks Consensus Estimate for ILMN’s full-year earnings has moved 12.27% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the latest available data, ILMN has gained about 61.25% so far this year. At the same time, Medical stocks have gained an average of 6.46%. As we can see, Illumina is performing better than its sector in the calendar year.

Looking more specifically, ILMN belongs to the Medical – Biomedical and Genetics industry, a group that includes 280 individual stocks and currently sits at #97 in the Zacks Industry Rank. On average, stocks in this group have lost 1.62% this year, meaning that ILMN is performing better in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to ILMN as it looks to continue its solid performance.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.